Skip to Content
Merck
  • Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.

Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.

Drugs (1990-01-01)
K Chatterjee, T De Marco
ABSTRACT

Enalapril is an effective angiotensin-converting enzyme (ACE) inhibitor which produces salutary, beneficial haemodynamic effects in patients with congestive heart failure. Enalapril also produces beneficial neurohumoral changes, as well as improving abnormal coronary haemodynamics and myocardial energetics that are frequently encountered in these patients. Administration of enalapril once or twice daily appears to be quite effective during maintenance therapy in patients with chronic congestive heart failure.

MATERIALS
Product Number
Brand
Product Description

USP
Enalaprilat, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Enalaprilat dihydrate, ≥98% (HPLC)
Enalaprilat dihydrate, European Pharmacopoeia (EP) Reference Standard